Who is ... Nathalie Schmidt

"I am fascinated by the intricate interplay between immune cell function and metabolism and how subtle metabolic alterations can have far reaching immunological consequences."


Dr. Dr. Nathalie Schmidtis a clinician scientist and research group leader at the Department I of Internal Medicine at University Hospital Cologne. Her research lies at the intersection of immunology, metabolism, and infectious diseases and seeks to understand how metabolic processes shape human T-cell immunity - with the ultimate goal of translating these insights into new strategies to strengthen immune responses against infections and cancer.
 

Research Focus

A central theme of Schmidt’s research is immunometabolism: the close and reciprocal relationship between cellular metabolism and immune function. T cells undergo profound metabolic changes when they become activated, differentiate, and respond to infections or tumors. At the same time, systemic metabolic conditions can alter the environment in which these immune responses develop.

Schmidt investigates how changes in nutrient availability and lipid metabolism influence human T-cell function. Her work has focused particularly on cholesterol metabolism and its role in regulating antiviral and antitumor immunity. By identifying metabolic pathways that determine T-cell functionality, she seeks to uncover molecular checkpoints that could potentially be targeted to restore or enhance immune responses.

Her current research extends these concepts to obesity and metabolic therapies. Obesity is associated with an increased risk of severe infections and cancer, yet the underlying mechanisms remain incompletely understood. On the other hand, metabolic therapies have revolutionized the treatment of obesity. Schmidt investigates how both, obesity and metabolic interventions, influence antiviral T cell phenotype, function and metabolism, and whether immunological alterations persist after weight loss.

A complementary focus of her work is the role of sex and gender in infectious diseases, immunity, and immunometabolism. Together, these research directions aim to identify populations at increased risk of impaired immunity and to develop more individualized strategies for preventing and treating infectious diseases and tumours. 

Selected Publications & Scientific Contributions

A major contribution to Schmidt’s research field is her first-author study published in Nature Communications in 2021. Together with colleagues at University College London and international collaborators, she identified acyl-CoA cholesterol acyltransferase (ACAT) as a metabolic checkpoint regulating viral replication and T cell function.

The study demonstrated that inhibiting cholesterol esterification could enhance the functionality of hepatitis B virus- and SARS-CoV-2-specific as well as hepatocellular carcinoma-specific T cells. At the same time, ACAT inhibition had a direct antiviral effect against hepatitis B virus and SARS-CoV-2. These findings revealed how targeting a single metabolic pathway could simultaneously affect a pathogen and strengthen the immune cells required to control infection and cancer.

Importantly, the study used patient-derived cells and human liver and tumor tissue, illustrating the translational approach that continues to characterize Schmidt’s research. Together, these studies established the scientific foundation for her current research: understanding metabolic regulation not simply as a consequence of immune activation, but as a potentially modifiable determinant of human immune function.

Scientific Career & Recognition

Schmidt studied medicine at the University of Freiburg, where she also completed her medical doctorate investigating tumor antigen-specific CD8+ T-cell responses in patients with hepatocellular carcinoma. She subsequently trained as a clinician scientist in internal medicine, gastroenterology, and infectious diseases at University Hospital Freiburg.

In 2016, she moved to the Division of Infection and Immunity at University College London, where she joined the group of Prof. Mala Maini. During more than six years in London, Schmidt investigated metabolic regulation of T-cell responses in chronic viral infection and cancer, with a particular focus on cholesterol metabolism.

In 2022, she received her PhD from University College London for her thesis “Targeting cholesterol esterification as a novel immune checkpoint in viral infections and cancer.” She returned to Germany in 2023 to join the Department I of Internal Medicine at University Hospital Cologne as a clinician scientist.

Her scientific development has been supported by several competitive fellowships and awards, including a German Research Foundation (DFG) Fellowship, a Bright Sparks Award from the British Society for Immunology, and a Keystone Symposia Scholarship. She has also been supported through the Cologne Clinician Scientist Program and the DFG Nachwuchsakademie Infektionsmedizin.

Since 2026, Schmidt has been a board-certified specialist in internal medicine and leads the Translational Immunometabolism research group at University Hospital Cologne.

Current Research & Funding

In 2026, Schmidt joined the CMMC as a Career Advancement Program (CAP) Group Leader. Her CAP 47 research program, “Translational Immunometabolism,” investigates how metabolic diseases, altered nutrient availability, and metabolic therapies shape human T-cell immunity.

Building on her previous work on cholesterol metabolism, her group seeks to define the mechanisms through which obesity alters immune function and to determine how modern metabolic interventions affect antiviral immunity with a focus on lipid metabolism. By combining mechanistic immunology with clinically relevant human studies, Schmidt aims to identify individuals at increased risk of impaired immune responses and uncover metabolic pathways that could be targeted to enhance immunity against infections, tumours and improve vaccine responses.

This research direction has recently received substantial additional support from the Else Kröner-Fresenius-Stiftung (EKFS) and the DFG. 

By bringing together metabolic medicine, infectious diseases, and human immunology, Schmidt’s research seeks to understand how an individual’s metabolic state shapes immune competence – and how this knowledge can be translated into more precise preventive and therapeutic strategies.